The Galien Forum USA 2019

October 24th 2019
Alexandria Center – New York City

 The Galien Forum, held every autumn at Alexandria Center for Life Science – New York, offers a full day of spirited discussions with Nobel Laureates, top policymakers, and leading industry executives who offer perspectives on the most significant health challenges of our time while highlighting the latest research and clinical pathways toward diagnosis, treatment, and cure.

See who attended the Forum

PANEL 1

Digital Health – Orchestrating patient-centricity from molecule to market

7:45 am – 8:50 am

Panel Introduction    Register

Prix Galien Statement – Richard Staub

Chair
MaryAnne Rizk, PhD
Senior Vice President Digital R&D Strategy
IQVIA

Panelists
Nancy Dreyer PhD, MPH, FISPE, Fellow DIA

Chief Scientific Officer
IQVIA

Emmanuel Fombu, MD, MBA
Physician, Author: The Future of Healthcare

Karl Hick
Chief Digital and Information Officer
Takeda

Jim Scholefield, MBA
Executive Vice President, Chief Information
and Digital Officer

Merck & Co.

Statement
Richard Staub
President of Research and Development Solutions
IQVIA

Panelists bios

PANEL 2

Can disruptive innovation positively impact healthcare costs?

8:55 am – 10:00 am

Panel Introduction    Register

Co-Chairs
Joel S. Marcus
Executive Chairman & Founder
Alexandria Real
Estate Equities, Inc./
Alexandria Venture Investments;
Co-Founder
Alexandria Summit

Lynne Zydowsky, PhD
Chief Science Officer
Alexandria Real
Estate Equities, Inc./
Alexandria Venture Investments;
President and Co-Founder
Alexandria Summit

Panelists
David R. Epstein, MBA
Executive Partner
Flagship Pioneering

Joshua J. Ofman, MD, MSHS
Chief of Corporate Strategy
and External Affairs
GRAIL

David Schenkein, MD
General Partner, Google Ventures;
Executive Chairman of the Board & Former Chief Executive Officer,
Agios Pharmaceuticals

Panelists bios

PANEL 3

“Drugging the undruggable” with novel approaches to small molecule design

10:15 am – 11:20 am

In the journey of drug discovery and development, scientists are continually uncovering new pathways for treatment, often with a focus on either dialing up or dialing back the activity of a specific molecular target. Historically, this has involved identifying a protein that has a “druggable” binding pocket that can be targeted with a small molecule, or to design antibodies that bind to a specific known antigen.

Panel Introduction    Register

Chair
Mikael Dolsten, MD, PhD
Chief Scientific Officer & President, Worldwide Research, Development and Medical (WRDM)
Pfizer

Panelists
Karin Briner, PhD
Vice President & Head, Global Discovery Chemistry
Novartis

Alessio Ciulli, PhD
Professor of Chemical & Structural Biology, School of Life Sciences
University of Dundee

Craig Crews, PhD
Founder and Chief Scientific Officer
Arvinas

Jennifer Petter, PhD
Chief Scientific Officer
Arrakis

Michael Ringel, JD, PhD
Senior Partner & Managing Director
BCG

Panelists bios

PANEL 4

The marriage of technology and medicine: Bringing out the best in each other

11:25 am – 12:35 pm

Panel Introduction   Register

Chair
Bengt Samuelsson, MD, PhD
Nobel Laureate
Former President,
Karolinska Institute
Former Chairman, Nobel Foundation

Panelists
Amy K. Butler, PhD
President of Biosciences
Thermo Fisher Scientific

Steve Rosenberg
Senior Vice President & General Manager
Oracle Health Sciences

Magnus Settergren, MD, PhD
Assoc Prof and Interventional Cardiologist
Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden

Eric Topol, MD
Executive Vice President and Chair
Innovative Medicine Scripps Research;
Director & Founder
Scripps Research Translational Institute;
Author, Deep Learning

Panelists bios

PANEL 5

How will we be paying for medicine 10 years from now?

1:15 pm – 2:20  pm

Panel Introduction    Register

Co-Chairs
Susan Desmond-Hellmann, MD, MPH
Chief Executive Officer
Bill & Melinda Gates Foundation
Prix Galien USA Committee Chair

Mike Rosenblatt, MD
Chief Medical Officer
Flagship Pioneering

Panelists
Albert Bourla, DVM, PhD
Chief Executive Officer
Pfizer

Jacqualyn Fouse, PhD
Chief Executive Officer
Agios

Christophe Weber, PharmD
Representative Director,
President & Chief Executive Officer
Takeda

Panelists bios

PANEL 6

Delivering on the patient promise of gene therapy

2:25 pm – 3:15 pm

Panel Introduction    Register

Chair
Kathy High, MD
President and Head of R&D
Spark Therapeutics

Panelists
Peter Marks, MD, PhD
Director, Center for Biologics Evaluation and Research (CBER)
U.S. FDA

Maria Grazia Roncarolo, MD
Professor of Pediatrics and Medicine
Stanford University School of Medicine

Robin L. Smith, MD, MBA
Founder
Neostem and Cura Foundation

Panelists bios

KEYNOTE

Keynote Dialogue: Life science companies: public health institutions or black hats?

3:20 pm – 4:15 pm

Panel Introduction    Register

Susan Desmond-Hellmann, MD, MPH
Chief Executive Officer
Bill & Melinda Gates Foundation
Prix Galien USA Committee Chair

Scott Gottlieb, MD
Former Commissioner
U.S. FDA

MedStartUp
PANEL

Prioritization and acceleration of biopharma asset performance through advanced analytics

12:15 pm – 1:15 pm

Panel Introduction  Register

Chair
Sergio Rossi, MBA
Managing Director & Partner
Boston Consulting Group

Panelists
Abel Archundia, MBA
Global Head of IT & Digital Transformation
Bayer Pharmaceuticals

Ülo Palm, MD, PhD, MBA
Senior Vice-President, Digital Sciences
Allergan

Satty Chandrashekhar
Managing Director and Partner
Boston Consulting Group

Joanna Wolkowski, MBA
Vice-President, Portfolio & Decision Analysis
Pfizer

Panelists bios